NurExone Reports Third Quarter 2023 Financial Results and Pr

TORONTO and HAIFA, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”)...

Related Keywords

Toronto , Ontario , Canada , Germany , United States , Israel , Belfast , United Kingdom , Israeli , Eva Reuter , Nurexone Exotherapy , Lior Shaltiel , Teodoro Forcht Dagi , Gadi Riesenfeld , Israel Institute Of Technology , Queen University Belfast , Inteligex Inc , Facebook , Advisory Committee , Twitter , Tel Aviv University , Israeli Innovation Authority , Youtube , Nurexone Biologic Inc , Company Or Nurexone , Linkedin , Company Annual Information Form , Thesis Capital Inc , Trademark Office , Company Exotherapy , Drug Administration , Israel Innovation Authority On , Mayo Clinic Alix School Of Medicine , Exone Biologic , United States Food , Orphan Drug Designation , New Drug , Drug Designation , Pre Investigational New Drug , Investigational New Drug , Eureka Grant , New Israeli Shekels , Israel Innovation Authority , Canada Based Inteligex , Scientific Advisory Board , Professor Teodoro Forcht Dagi , Mayo Clinic Alix School , University Belfast , Eran Ovadya , Common Share , Each Class , Classb Warrant , Each Option , Common Shares , Quarter Fiscal , Israel Institute , Executive Officer , Annual Information Form ,